AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
September 21 2022 - 7:45AM
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or
the “Company”), an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of cancers,
immune disorders, and viral diseases, including COVID-19, the
disease caused by the SARS-CoV-2 virus, today announced that it
will participate in the Virtual Investor Long COVID Event on
Wednesday, September 28, 2022 at 3:00 PM ET.
As part of the virtual event, Thomas K. Equels,
MS JD, Chief Executive Officer of AIM ImmunoTech, will be joined by
Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center in
Charlotte, N.C. and Dr. Daniel Peterson of Sierra Internal Medicine
in Incline Village, Nev. to discuss the Company’s ongoing
FDA-authorized treatment protocol (Expanded Access Program) for its
investigational drug, Ampligen, which extends to the use and
evaluation of the drug in patients with symptoms of “long
COVID”.
In addition to the moderated portion of the
event, investors and interested parties will have the opportunity
to submit questions live during the event. The Company will answer
as many questions as possible during the event.
A live video webcast of the Virtual Investor
Long COVID Event will be available on the Events &
Presentations page of the Investor Relations section of the
Company’s website (aimimmuno.com). A webcast replay will be
available two hours following the live presentation and archived
for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders, and viral diseases,
including COVID-19. The Company’s lead product,
Ampligen® (rintatolimod) is an immuno-modulator with broad
spectrum activity being developed for globally important cancers,
viral diseases and disorders of the immune system.For more
information, please visit aimimmuno.com and connect with the
Company on Twitter, LinkedIn, and Facebook.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2024 to May 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2023 to May 2024